Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway.
Department of Obstetrics and Gynecology, St Olav's University Hospital, Trondheim, Norway.
Acta Obstet Gynecol Scand. 2024 Jun;103(6):1092-1100. doi: 10.1111/aogs.14800. Epub 2024 Feb 17.
Women with polycystic ovary syndrome (PCOS) have more pregnancy complications like gestational diabetes, hypertension, and preterm labor than other women. Metformin has been used in an attempt to improve pregnancy outcomes. Our study aims to explore childbirth experiences in women with PCOS compared with a reference population. It also explores the potential influence of metformin, obesity, pregnancy complications, and the duration and mode of birth on childbirth experiences.
This study is a cohort study combining data from two randomized trials conducted in Norway, Sweden and Iceland. The PregMet2 study (ClinicalTrials.gov, NCT01587378) investigated the use of metformin vs. placebo in pregnant women with PCOS. The Labour Progression Study (ClinicalTrials.gov, NCT02221427) compared the WHO partograph to Zhang's guidelines for progression of labor and were used as the reference population. A total of 365 women with PCOS and 3604 reference women were included. Both studies used the Childbirth Experience Questionnaire (CEQ). Main outcome measures were total CEQ score and four domain scores. The CEQ scores were compared using Mann-Whitney U test for women in Robson group 1 with PCOS (n = 131) and reference women (n = 3604). CEQ scores were also compared between metformin-treated (n = 180) and placebo-treated (n = 185) women with PCOS, and for different subgroups of women with PCOS.
There was no difference in total CEQ score between women with PCOS and reference women-Wilcoxon-Mann-Whitney (WMW)-odds 0.96 (95% confidence interval [CI] 0.78-1.17). We detected no difference in CEQ scores between the metformin- and placebo-treated women with PCOS (WMW-odds 1.13, 95% CI 0.89-1.43). Complications in pregnancy did not affect CEQ (WMW-odds 1, 95% CI 0.76-1.31). Higher body mass index (WMW-odds 0.75, 95% CI 0.58-0.96), longer duration of labor (WMW-odds 0.69, 95% CI 0.49-0.96), and cesarean section (WMW-odds 0.29, 95% CI 0.2-0.42) were associated with lower CEQ scores in women with PCOS.
Women with PCOS experience childbirth similarly to the reference women. Metformin did not influence childbirth experience in women with PCOS, neither did pregnancy complications. Obesity, long duration of labor or cesarean section had a negative impact on childbirth experience.
多囊卵巢综合征(PCOS)女性比其他女性更容易出现妊娠并发症,如妊娠糖尿病、高血压和早产。二甲双胍已被用于尝试改善妊娠结局。我们的研究旨在探讨 PCOS 女性与参考人群的分娩体验,并探讨二甲双胍、肥胖、妊娠并发症以及分娩持续时间和方式对分娩体验的潜在影响。
这是一项在挪威、瑞典和冰岛进行的两项随机试验数据相结合的队列研究。PregMet2 研究(ClinicalTrials.gov,NCT01587378)调查了二甲双胍与安慰剂在 PCOS 孕妇中的应用。劳动进展研究(ClinicalTrials.gov,NCT02221427)比较了 WHO 产图与 Zhang 产程指南,并将其作为参考人群。共纳入 365 名 PCOS 女性和 3604 名参考女性。两项研究均使用分娩体验问卷(CEQ)。主要观察指标为总 CEQ 评分和四个领域评分。使用 Robson 组 1 中 PCOS 女性(n=131)和参考女性(n=3604)的 Mann-Whitney U 检验比较 CEQ 评分。还比较了二甲双胍治疗(n=180)和安慰剂治疗(n=185)PCOS 女性之间的 CEQ 评分,以及不同亚组的 PCOS 女性之间的 CEQ 评分。
PCOS 女性与参考女性的总 CEQ 评分无差异-Wilcoxon-Mann-Whitney(WMW)比值 0.96(95%置信区间[CI]0.78-1.17)。我们没有发现二甲双胍治疗和安慰剂治疗 PCOS 女性之间的 CEQ 评分差异(WMW 比值 1.13,95%CI0.89-1.43)。妊娠并发症并未影响 CEQ(WMW 比值 1,95%CI0.76-1.31)。较高的体重指数(WMW 比值 0.75,95%CI0.58-0.96)、较长的产程(WMW 比值 0.69,95%CI0.49-0.96)和剖宫产(WMW 比值 0.29,95%CI0.2-0.42)与 PCOS 女性的 CEQ 评分较低相关。
PCOS 女性的分娩体验与参考女性相似。二甲双胍对 PCOS 女性的分娩体验没有影响,妊娠并发症也没有影响。肥胖、较长的产程或剖宫产对分娩体验有负面影响。